ULURU Inc. Announces The First Shipment Of Veterinary Product

ADDISON, Texas, Nov. 5, 2012 /PRNewswire/ -- ULURU Inc. ("ULURU") (OTCQB: ULUR), announced today that the first shipment of Derazil™, the veterinary form of Altrazeal^®, has been shipped to its partner company.

As announced on September 8, 2010, ULURU entered into a partnership with an animal health company for the product, Derazil™, an advanced, scientifically engineered material that is unique among all other wound dressings in terms of properties and performance. Derazil™ incorporates into the micro-porous skin-like film formed when the powder transforms, the features and benefits of a desired "ideal" wound dressing. In initial testing in a variety of small and large animals including horses, pigs and dogs positive healing results have been achieved. In controlled comparative studies conducted in numerous pig models, Derazil™ out-performed the competitive dressing.

Commenting on the first shipment, Kerry P. Gray, President and CEO of ULURU, stated, "We are very pleased to have achieved this important milestone. We look forward to working with our partner to establish Derazil™ as a market leading product in the veterinary wound care market. The data generated to date indicates that this technology provides similar improved clinical benefits in animals as has been generated in humans."

Altrazeal^® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressings. Altrazeal^® competes in the advanced human wound dressing market which worldwide is estimated to be $6.5 billion growing annually at 13%. Altrazeal^® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous ulcers and geriatric wounds.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through its innovative Nanoflex^® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal^® out performs competitive products in pig studies, achieves positive results in animal models, that Derazil™ can be a market leading product in the veterinary market, and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

SOURCE ULURU Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED